AR106956A1 - Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación - Google Patents

Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación

Info

Publication number
AR106956A1
AR106956A1 ARP160103793A ARP160103793A AR106956A1 AR 106956 A1 AR106956 A1 AR 106956A1 AR P160103793 A ARP160103793 A AR P160103793A AR P160103793 A ARP160103793 A AR P160103793A AR 106956 A1 AR106956 A1 AR 106956A1
Authority
AR
Argentina
Prior art keywords
mutations
open reading
viruses
orf
phenotypes
Prior art date
Application number
ARP160103793A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of AR106956A1 publication Critical patent/AR106956A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Abstract

En la presente se proporcionan virus sincitiales respiratorios (VSR) que tienen un fenotipo atenuado que contiene mutaciones en el marco de lectura abierto M2-2 que interfieren con la expresión de la proteína M2-2. Las mutaciones M2-2 pueden estar presentes en combinación con mutaciones en otro loci. Usando los métodos descriptos en la presente, se proporcionan combinaciones de mutaciones para lograr niveles deseados de atenuación. Las cepas del VSR recombinante descriptas en la presente son adecuadas para usar como vacunas vivas atenuadas contra el VSR. También se proporcionan secuencias de polinucleótidos de los virus descriptos, como así también métodos para producir y usar los virus.
ARP160103793A 2015-12-11 2016-12-12 Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación AR106956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266199P 2015-12-11 2015-12-11

Publications (1)

Publication Number Publication Date
AR106956A1 true AR106956A1 (es) 2018-03-07

Family

ID=57714677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103793A AR106956A1 (es) 2015-12-11 2016-12-12 Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación

Country Status (10)

Country Link
US (2) US10655109B2 (es)
EP (1) EP3386539A1 (es)
JP (2) JP7079197B2 (es)
KR (1) KR20180085803A (es)
CN (1) CN109310752B (es)
AR (1) AR106956A1 (es)
AU (1) AU2016366771B2 (es)
BR (1) BR112018011674A2 (es)
CA (1) CA3007408A1 (es)
WO (1) WO2017100759A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222573A1 (en) * 2017-05-29 2018-12-06 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
WO2021248086A2 (en) * 2020-06-05 2021-12-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated respiratory syncytial virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
CA2430115C (en) * 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
DE10118446A1 (de) 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
PT3511015T (pt) * 2012-04-13 2021-04-05 Us Health Vacina viva e atenuada e geneticamente estável contra o vírus sincicial respiratório e a sua produção
WO2015041924A2 (en) * 2013-09-18 2015-03-26 Medimmune, Llc Recombinant respiratory syncytial virus (rsv) and caccines
US10947512B2 (en) 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods

Also Published As

Publication number Publication date
AU2016366771A1 (en) 2018-07-12
RU2018125246A3 (es) 2020-05-25
US11332721B2 (en) 2022-05-17
CN109310752B (zh) 2022-12-16
JP2018536428A (ja) 2018-12-13
WO2017100759A1 (en) 2017-06-15
JP7079197B2 (ja) 2022-06-01
CN109310752A (zh) 2019-02-05
JP2022088376A (ja) 2022-06-14
JP7357709B2 (ja) 2023-10-06
EP3386539A1 (en) 2018-10-17
RU2018125246A (ru) 2020-01-15
US20200283740A1 (en) 2020-09-10
US10655109B2 (en) 2020-05-19
CA3007408A1 (en) 2017-06-15
BR112018011674A2 (pt) 2018-12-04
KR20180085803A (ko) 2018-07-27
AU2016366771B2 (en) 2022-04-07
US20190040365A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
CO2018006706A2 (es) Virus mutados, método de preparación y uso de los mismos
CO2018001534A2 (es) Una composicion de vacuna arboviral
MX2018007627A (es) Vacuna contra el virus del zika.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
UY37360A (es) Nucleósidos sustituidos, nucleótidos y análogos de estos
MX2021010060A (es) Produccion de virus en huevos aviares.
CO2018003451A2 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
ECSP11011033A (es) Virus sincitial respiratorio vivo atenuado
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
BR112019009131A2 (pt) vacina contra o parvovírus suíno, o vírus da síndrome respiratória e reprodutiva dos suínos e métodos de produção das mesmas
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
AR106956A1 (es) Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
BR112017004452A2 (pt) vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
AR099680A1 (es) Muteínas mejoradas de factor viii de coagulación
CL2017001722A1 (es) Un método de activación de bacterias ácido lácticas
MX2016009464A (es) Composiciones para el uso en el tratamiento de afecciones alergicas.
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c